Status:

UNKNOWN

MyndMove Therapy for Severe Hemiparesis of the Upper Limb Following Stroke

Lead Sponsor:

University Health Network, Toronto

Conditions:

Stroke

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to examine the efficacy of MyndMove therapy in the early sub-acute, late sub-acute and chronic post-stroke patients. Other objectives include assessing the required doses ...

Detailed Description

The purpose of this study is to examine the efficacy of MyndMove therapy in the early sub-acute, late sub-acute and chronic post-stroke patients. Other objectives include assessing the required doses ...

Eligibility Criteria

Inclusion

  • Ischemic or hemorrhagic stroke confirmed by MRI or CT scan
  • Sub-acute subjects at least 10 days post stroke. Chronic subjects at least 6 months post stroke
  • Chedoke-McMaster Stroke Assessment Stage 1-2 (arm and hand)
  • Severe hemiplegia of the upper extremity defined as UE-FMA score of less than or equal to 19
  • Subject is able to follow instructions
  • Subject is able to sit and participate in one hour of upper limb therapy
  • Anticipated to be discharged home or already at home following conventional inpatient rehabilitation
  • Willing to attend outpatient therapy if chronic or late sub-acute
  • Subject is able and willing to give written informed consent
  • Men and women aged 18 or older

Exclusion

  • Global Aphasia
  • Previous history of clinical stroke either ischemic infarct, hemorrhagic and subarachnoid bleeding
  • Upper extremity injury or condition prior to stroke that limits the function of the hand or arm
  • Life expectancy of less than 12 months due to other illness
  • Subject has malignant skin lesion on the affected upper extremity
  • Subject has history of seizure disorder and on seizure medications
  • Subject has existing electrical stimulation devices (ICD, Pacemaker, Spinal Stimulation)
  • Neurologic condition that may affect motor response (e.g. Parkinson's, ALS, MS)
  • Subject has rash or open wound at any potential electrode site
  • In the judgment of the medical provider, subject has medical complications that may interfere with the execution of the study
  • Botulinum toxin (Botox) injection into affected upper extremity at least 3 months before the study or during the study
  • Currently enrolled in another upper limb study
  • Enrolled in the past six months in a clinical study involving drugs or biologics

Key Trial Info

Start Date :

August 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2018

Estimated Enrollment :

75 Patients enrolled

Trial Details

Trial ID

NCT03323632

Start Date

August 1 2014

End Date

December 31 2018

Last Update

October 27 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Toronto Rehab Inst, UHN

Toronto, Ontario, Canada, M5G2A2